Abraxane generic
Abraxane is an anti-cancer drug owned by Bristol Myers Squibb Co. It contains the active ingredient paclitaxel and was first approved for market use on 07 January, 2005. The drug is available in powder form for intravenous administration.
When will Abraxane generic be available?
The generic version of Abraxane is expected to be released after 12 July, 2034. This release date is based on the expiration date of the drug's last known patent, US9511046*PED, which expires on 2034-07-12.
Abraxane uses
Abraxane is used for the treatment of various types of cancer including pancreatic cancer, lung cancer, and breast cancer. The effectiveness of this drug comes from its active ingredient, paclitaxel.
Abraxane patent expiration
Abraxane holds a total of 22 drug patents, 3 of which have already expired. The remaining patents include compositions and methods of delivery of pharmacological agents, as well as methods of treating different types of cancer. The last patent to expire will be US9511046*PED in July 2034. Below are the details of the patent: